Today, Explained A postpartum pill
Aug 14, 2023
Nancy Byatt, a Professor of Psychiatry at UMass Chan Medical School, dives deep into the groundbreaking FDA-approved pill for postpartum depression, Zoranolone. She discusses how this innovative treatment offers faster relief compared to traditional options, addressing the long-neglected issue of women's mental health. The conversation also highlights the physiological and psychosocial challenges faced by new mothers, advocating for better, more accessible mental health resources and a more inclusive understanding of postpartum care.
AI Snips
Chapters
Transcript
Episode notes
Postpartum Depression Experience
- Karen Kurdoff experienced postpartum depression after her first child's birth.
- Accessing extended disability and dealing with isolation compounded her struggles.
Zoranolone's Rapid Action
- Zoranolone works faster than other postpartum depression medications.
- It shows improvement within three days and sustained effects at 15 and 45 days.
Evolution of Women's Healthcare
- Increased recognition of women's health and perinatal mental health has led to the development of new treatments.
- This shift acknowledges the physiological differences during pregnancy and postpartum.